NF-kB, a potential therapeutic target for the treatment of multiple sclerosis

Yan, J. and Greer, Judith M. (2008) NF-kB, a potential therapeutic target for the treatment of multiple sclerosis. CNS & Neurological Disorders - Drug Targets, 7 6: 536-557. doi:10.2174/187152708787122941

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
n2008_CNSND-DT_7_536.pdf review of potential role of NF-kB as a therapeutic target in MS application/pdf 364.54KB 0

Author Yan, J.
Greer, Judith M.
Title NF-kB, a potential therapeutic target for the treatment of multiple sclerosis
Journal name CNS & Neurological Disorders - Drug Targets   Check publisher's open access policy
ISSN 1871-5273
Publication date 2008-01-01
Year available 2008
Sub-type Critical review of research, literature review, critical commentary
DOI 10.2174/187152708787122941
Open Access Status File (Author Post-print)
Volume 7
Issue 6
Start page 536
End page 557
Total pages 22
Editor C. Evans
J. Kehne
S. Skaper
M. Bradbury
Place of publication Bussum, The Netherlands
Publisher Bentham Science Publishers
Language eng
Subject C1
920108 Immune System and Allergy
920111 Nervous System and Disorders
110703 Autoimmunity
110903 Central Nervous System
Abstract Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) that afflicts over 2 million people worldwide. On the basis of the temporal course of disease, MS can be subdivided into three clinical groups: relapsing remitting MS (RR-MS), secondary progressive MS and primary progressive MS. There is a high degree of clinical diversity within these subgroups. The pathogenesis of MS in most patients is likely to result from autoreactive, activated CD4(+) T cells moving from the periphery across the blood brain barrier into the CNS. Most therapeutic agents used in MS (e.g. immunosuppressive and immunomodulatory drugs and cell cycle interruption drugs) are only used for RR-MS. These treatments show some efficiency in lessening the relapse rate in RR-MS and time to progression, but cannot cure MS. Thus, there is a need for new efficient treatments for all types of MS. An increasing number of studies indicate that nuclear factor-kappa B plays an important role in controlling expression of genes relevant to the pathogenesis of autoimmunity. Genetic factors related to NF-kappa B may also be determinants of MS susceptibility, as polymorphisms in the molecules involved in regulation of the NF-kappa B signal transduction pathway differ between RRMS and progressive MS. Herein, the role of NF-kappa B in MS will be reviewed and its potential as a new therapeutic target in MS will be considered and compared with existing treatments.
Keyword Neurosciences
Pharmacology & Pharmacy
Neurosciences & Neurology
Pharmacology & Pharmacy
NEUROSCIENCES
PHARMACOLOGY & PHARMACY
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: 2009 Higher Education Research Data Collection
Excellence in Research Australia (ERA) - Collection
UQ Centre for Clinical Research Publications
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 51 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 53 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 09 Apr 2009, 10:16:37 EST by Carmen Buttery on behalf of UQ Centre for Clinical Research